Cellular uptake of liposomal daunorubicin and the induction of apoptosis

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 6, Issue 4, 1999, Pages 213-226

  Gray, Atherton ^a   Landfair, Darla J ^a   Wiles, Marc E ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Cytotoxicity; Daunorubicin; Doxorubicin; Liposome; Tumor Cell

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DNA FRAGMENT; DOXORUBICIN; LIPOSOME; MACROGOL;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LYSATE; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE; TUMOR CELL CULTURE;

EID: 0033406423     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/107175499266814     Document Type: Article

References (39)

1. Adler-Moore, J. 1994. AmBisome targeting to fungal infections. Bone Marrow Transplant 14 Suppl 5:S3-S7.
2. Adler-Moore, J. P., Chiang, S. M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J., and Proffitt, R. T. 1991. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28 Suppl B:63-71.
3. Allen, T. M., Hansen, C. B., and Guo, L. S. 1993. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150:9-16.
4. Arcamone, P., Animati, F., Capranico, G., Lombardi, P., Pratesi, G., Manzini, S., Supino, R., and Zunino, F. 1997. New developments in antitumor anthracyclines. Pharmacol. Ther. 76(1-3):117-124.
5. Arcamone, F., and Cassinelli, G. 1998. Biosynthetic anthracyclines. Curr. Med. Chem. 5(5):391-419.
6. Arcamone, F. M. 1998. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 80(3):201-206.
7. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58(13):2825-2831.
8. Bettaieb, A., Plo, I., Mansat-De Mas, V., Quillet-Mary, A., Levade, T., Laurent, G., and Jaffrezou, J. P. 1999. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis. Mol. Pharmacol. 55(1):118-125.
9. Cabanes, A., Tzemach, D., Goren, D., Horowitz, A. T., and Gabizon, A. 1998. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res. 4(2):499-505.
10. Chaires, J. B. 1998. Drug-DNA interactions. Curr. Opin. Struct. Biol. 8(3):314-320.
11. Cortes, J., Kantarjian, H., O'Brien, S., Giles, F., Koller, C., Beran, M., Keating, M., and Estey, E. 1998. High-dose liposomal daunorubicin (DNX) and Ara-C (HDAC) for refractory or relapsed acute leukaemias: A dose searching study. Blood 92:A957.
12. Dorr, R. T., and Von Hoff, D. D. 1994a. Daunorubicin HCl. In Cancer Chemotherapy Handbook, ed. R. T. Dorr and D. D. Von Hoff. Norwalk, CT: Appleton & Lange.
13. Dorr, R. T., and Von Hoff, D. D. 1994b. Doxorubicin. In Cancer Chemotherapy Handbook, ed. R. T. Dorr and D. D. Von Hoff. Norwalk, CT: Appleton & Lange.
14. Forssen, E., Adler-Moore, J., Lee, M. J., Franke, K., McAndrews, B., Oka, M., Toward, M., Krasieva, T., and Tromberg, B. 1996a. In vivo trafficking of daunorubicin liposomes within Kaposi's sarcoma xenografts (meeting abstract). Proc. Am. Assoc. Cancer Res. 37:A2057 1996.
15. Forssen, E. A., Coulter, D. M., and Proffitt, R. T. 1992. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 52(12):3255-3261.
16. Forssen, E. A., Male-Brune, R., Adler-Moore, J. P., Lee, M. J., Schmidt, P. G., Krasieva, T. B., Shimizu, S., and Tromberg, B. J. 1996b. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56(9):2066-2075.
17. Forssen, E. A., Male-Brune, R., Adler-Moore, J., Lee, M., Frank, K., Dvornikova, T., and Tromberg, B. 1995. In vitro and in vivo fluorescent imaging methods for evaluating the biological disposition of daunorubicin liposomes (DaunoXome) Proc. Am. Assoc. Cancer. Res. 36:A1839 1995.
18. Forssen E. A., and Ross M. E. 1994. Daunoxome treatment of solid tumors: Preclinical and clinical investigations. J. Liposome Res. 4(1):481-512.
19. Gabizon, A., Goren, D., Cohen, R., and Barenholz, Y. 1998. Development of liposomal anthracyclines: from basics to clinical applications. J. Cont. Release 53(1-3):275-279.
20. Gabizon, A., and Martin, F. 1997. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54 Suppl 4:15-21.
21. Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tupule, A., Esplin, J. A., Liebman, H. A., Forssen, E. A., Ross, M. E., and Levine, A. M. 1995. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13:996-1003.
22. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., Hayden von Roenn, J., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., Rarick, M. U., Myers, A. M., Sheperd, F., Sawka, C., Pike, M. C., and, Ross M. E. 1996. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14(8):2353-2364.
23. Goren, D., Horowitz, A. T., Zalipsky, S., Woodle, M. C., Yarden, Y., and Gabizon, A. 1996. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 74(11):1749-1756.
24. Guaglianone, P., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeffers, S., Desh, S., and Muggia, F. 1994. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Investigational New Drugs 12:103-110.
25. Horowitz, A. T., Barenholz, Y., and Gabizon, A. A. 1992. In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. Biochim. Biophys. Acta 1109:203-209.
26. James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., and Stewart, J. S. W. 1994. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol. (Royal College of Radiologists) 6(5):294-296.
27. st Edition Vol. 1. Amsterdam: Elsevier Science B.V.
28. Malonne, H., and Atassi, G. 1997. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 8(9):811-822.
29. Martin, F., and Gabizon, A. 1992. Human pharmacokinetics of Stealth liposomes containing doxorubicin. J. Cell Biochem., Suppl. 16E:94.
30. McBride, N., Ward, M., Schey, S., Gran, I., Gray, A., Hughes, A., Mills, M., Cavenagh, J., Newland, A., and Kelsey, S. 1998. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prenisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin's lymphoma. Blood 92:A2560.
31. Papahadjopoulos, D., Allen,-T. M., and Gabizon, A. 1991. Sterically stabilised liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88:11460-11464.
32. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., Wood, W. I., et al. 1995. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92(5):1327-1331.
33. Park,J. W., Hong, K., Kirpotin, D. B., Meyer, O., Papahadjopoulos, D., and Benz, C. C. 1997. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 118(2):153-160.
34. Quillet-Mary, A., Mansat, V., Duchayne, E., Come, M. G., Allouche, M., Bailly, J. D., Bordier, C., and Laurent, G. 1996. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 10(3): 417-425.
35. Tritton, T. R. 1991. Cell surface actions of adriamycin. Pharmacol. Ther. 49(3):293-309.
36. Turner, A. F., Presant, C. A., Proffitt, R. T., Williams, L. E., Winsor, D. W., and Werner, J. L. 1988. In-111 -labeled liposomes: dosimetry and tumor depiction. Radiology 166:761-765.
37. Vichi, P., Robison, S., and Tritton, T. R. 1989. Temperature dependence of adriamycin-induced DNA damage in L1210 cells. Cancer Res. 49(20):5575-5580.
38. Von Hoff, D. D. 1984. Use of daunorubicin in patients with solid tumors. Seminars in Oncology 11(4):23-27.
39. Wiles, M. E., Bell, C., Landfair, D., Lynam, E., and Bendele, R. 1997. Anthracycline efficacy in vitro: liposomal/non-liposomal daunorubicin (DnR) and doxorubicin (DoX) cytotoxicity for multiple tumor cell types. Drug Delivery 4(4):255-262.